PCP vs Telehealth for GLP-1: Pros, Cons, and How to Choose
Many of you have an existing relationship with a primary care provider and are wondering whether to bring your GLP-1 question there or turn to a telehealth program. Others have no PCP at all, and some have no insurance: the U.S. Census Bureau reports that 92.0 percent of people had health insurance for some or all of 2024, which leaves 8.0 percent who went the whole year without it[1]. The answer is not one-size-fits-all. It depends on whether you have insurance, whether you already have a provider who knows your history, what your health situation looks like, and how you want follow-up care to work.
This page compares the two paths honestly. We’ll look at real pros and cons, the cost and insurance differences, and the questions that help you figure out which route makes sense for your situation. A specialist (for example, an obesity medicine or endocrinology practice) is a third option; most of what applies to the primary care path below applies there too.
Transformation Health is an independent guide, not a provider: we do not prescribe, sell medication, or bill insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
Transformation Health does not accept payment from providers. How we make money.
The Primary Care Path: Honest Pros
You have an established health history. Your PCP knows your medical past, other medications you take, chronic conditions, and family history. That context matters when starting a new medication. If you have several health issues that need management alongside your weight, your PCP can handle them in one relationship.
Insurance and prior authorization. If your plan covers GLP-1 medications for weight management, your PCP or specialist can prescribe within that system. Their office can submit the prior authorization request your plan may require, supply the documentation the plan asks for, and help with an appeal if the plan says no. Our prior authorization guide covers what plans usually require and the federal time limits.
In-person evaluation. An in-person appointment allows your PCP to do a physical exam, take vital signs, and pick up on things a telehealth intake form cannot. That’s a real clinical advantage. Your PCP can also order labs through the lab your insurance uses.
Trust and continuity. Some people prefer face-to-face relationships with their providers. If that’s you, and your PCP is responsive, staying in that relationship has real value.
The Primary Care Path: Honest Cons
Wait times vary. How soon you can get a visit focused on weight management depends on your clinic’s schedule and whether you are already an established patient. Ask the office how far out the next appointment is, and whether a nurse practitioner or physician assistant in the practice has earlier openings.
Variable familiarity with GLP-1. Many PCPs are comfortable prescribing GLP-1 medications for type 2 diabetes. For weight management, comfort levels vary. Your PCP may not have deep experience with the escalation schedules, side effect management, or monitoring specific to GLP-1 weight management. If not, a referral to a specialist is a reasonable ask.
Limited appointment time. A standard primary care visit often covers several issues at once, which can leave little time to talk through the GLP-1 decision, your goals, the dosing schedule, and what to expect. It can help to book a visit just for this topic and bring your questions written down.
Prior authorization can add time. If your insurance covers GLP-1 medications but requires prior authorization, the plan has to approve the request before it pays. For many employer plans, federal rules give the plan up to 15 days to decide (one 15-day extension is allowed), or 72 hours if the request is urgent[2]. Approval is not guaranteed. Some plans require documented attempts at other treatments first, and some exclude weight management drugs entirely. If you are denied, an internal appeal for a service you have not received yet must be decided within 30 days[3].
Follow-up schedules vary. Many primary care offices do not offer structured weight management coaching, and follow-up visits may be spaced further apart than you expect. Ask how often your PCP wants to see you while you are increasing the dose, and how to reach the office about side effects between visits.
Lab costs are billed separately. Labs ordered through your PCP’s office usually go through insurance, so copays or deductibles can apply on top of your visit and medication costs.
The Telehealth Weight Management Path: Honest Pros
Convenience. Most telehealth programs start with an online health questionnaire you can complete without waiting for an office appointment. A licensed provider reviews your information and decides whether a prescription is appropriate. If you are prescribed, the medication is filled by a pharmacy, which may be a retail pharmacy for brand-name products or a compounding pharmacy for compounded products. Timing varies by program, pharmacy, and shipping.
Focus on weight management. Telehealth weight management programs are set up for this specific use case. Ask who the prescribers are (a physician, nurse practitioner, or physician assistant), how much of their work is GLP-1 care, and how they handle dose escalation and side effects.
Cost structure you can compare. Many cash-pay programs charge a monthly fee. Some bundle the provider visits, medication, and labs into that fee; others charge separately for each, or add membership or shipping fees. Prices vary by program and dose. Compare the total cost: medication, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms. Our cash-pay telehealth cost guide explains the pricing models.
An option if insurance does not cover it. This matters if you are uninsured, underinsured, or your plan excludes weight management GLP-1 medications. Many telehealth programs are cash-pay, so there is no prior authorization step. Some programs do work with insurance; ask before you sign up.
Support between visits. Some programs include nutrition guidance, coaching, or messaging with the care team. Others offer only the prescription and periodic check-ins. Ask what is included and whether it costs extra.
Geographic reach. If you live in a rural area or somewhere with limited PCP availability, telehealth can give you access to licensed providers without travel. Ask whether the provider who would prescribe for you is licensed in your state, and which states the program serves.
The Telehealth Weight Management Path: Honest Cons
No physical exam. The intake relies on self-reported information and, at many programs, lab results. A telehealth provider cannot check your vital signs, listen to your heart, or find incidental findings a physical exam might catch. If you have several health conditions, consider whether an in-person evaluation would give your prescriber a fuller picture.
No continuity with broader care. Your telehealth provider focuses on the GLP-1 prescription. They are not your PCP. They usually do not manage your diabetes, hypertension, or other chronic conditions. If you need that broader coordination, you still need a PCP.
Compounded medications are not FDA-approved. This is the big one if a program prescribes compounded GLP-1 medications. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. Semaglutide and tirzepatide have been studied in clinical trials of FDA-approved brand-name products; compounded versions are different products, have not gone through that review, and may differ in formulation, purity, and potency. Understand this before you choose. The section below covers availability.
Not ideal for complex medical situations. If you have multiple health conditions, take many other medications, or have unusual medical complexity, you may be better served by in-person care where the provider can coordinate across your full health picture.
Brand-Name and Compounded Availability
Through a PCP or specialist, prescriptions are usually for FDA-approved brand-name products such as Wegovy (semaglutide) or Zepbound (tirzepatide), filled at a retail or mail-order pharmacy and billed to insurance when the plan covers it. Telehealth programs vary: some prescribe brand-name products, some prescribe compounded semaglutide or tirzepatide, and some offer both. Ask which one a program would prescribe and which pharmacy fills it.
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. They may differ in formulation, purity, and potency.
Regulatory status is subject to change. On December 19, 2024, the FDA reissued its determination that the tirzepatide injection shortage was resolved; it said its enforcement discretion period for 503A pharmacies ended after a March 5, 2025 court decision and for 503B outsourcing facilities on March 19, 2025[4]. On February 21, 2025, the FDA determined that the semaglutide injection shortage was resolved; it said its 503A period ended after an April 24, 2025 court decision (the original end date was April 22, 2025) and its 503B period ended May 22, 2025[4]. The FDA page was most recently updated April 1, 2026; check it for the current statement[4]. Availability of compounded GLP-1 medications depends on federal and state law and FDA action, and cannot be guaranteed.
Whichever route you take, the brand-name labels list the same core safety information. Wegovy and Zepbound each carry a boxed warning about the risk of thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Label warnings include pancreatitis, gallbladder disease, and kidney injury from dehydration[5][6]. Your prescriber should go over the full label with you.
Side-by-Side Comparison
Primary Care
- Getting started: Depends on appointment availability, plus prior authorization if your insurance requires it
- Cost: Depends on your insurance; copays and deductibles vary
- Physical exam: Yes
- Insurance and prior authorization: Yes; the office can submit prior authorization and help with appeals
- Medication: Usually FDA-approved brand-name products
- Ongoing monitoring: Varies by practice; ask how often
- Structured coaching: Rarely included
- Often a fit for: People with insurance coverage, several health conditions, or an established PCP relationship
Telehealth Service
- Getting started: Online questionnaire, then a licensed provider decides; pharmacy and shipping add time
- Cost: Prices vary by program and dose; compare medication, visits, labs, shipping, membership fees, and cancellation terms
- Physical exam: No
- Insurance and prior authorization: Many programs are cash-pay; some work with insurance
- Medication: Brand-name, compounded (not FDA-approved), or both, depending on the program
- Ongoing monitoring: Varies by program; ask how often and how
- Structured coaching: Included at some programs, extra or absent at others
- Often a fit for: People who are uninsured or underinsured, want to avoid an appointment wait, or live in rural or underserved areas
Who Should Choose Which Path
Consider your PCP first if:
- You have insurance that covers GLP-1 weight management and you want to use it
- You have several health conditions that need coordination with your broader care
- You prefer in-person evaluation and an existing provider relationship
- You are already scheduled with your PCP soon and want to bring it up in that visit
- You have tried the telehealth route and want a second opinion from your own provider
Consider telehealth if:
- You have no insurance or insurance that doesn’t cover weight management GLP-1 medications
- You don’t want to wait for an office appointment to get started
- You live in a rural or underserved area with limited PCP availability
- You have already tried bringing this up with a PCP and didn’t get what you needed
- You want to compare cash-pay programs on total cost and what each includes
- You want coaching or support between visits and can find a program that includes it
The Continuity-of-Care Question
One legitimate concern in the medical community is whether telehealth-only GLP-1 prescribing, without integration into a person’s broader medical care, creates gaps in monitoring and oversight. This is worth addressing directly because both PCPs and patients have raised real questions.
What PCPs and Medical Organizations Are Saying
In a January 2025 survey of more than 2,000 U.S. primary care physicians, released by Omada Health in February 2025, two-thirds (67%) agreed or strongly agreed that getting GLP-1 prescriptions for weight loss through a third-party telehealth provider may put their patients’ health at risk[7]. The top concerns cited were:
- Overprescribing (56%): Clinically inappropriate prescribing, for example to people who may not meet medical criteria or who have contraindications that a full health history review would catch.
- Continuity of care (50%): Follow-up visits, dose titration, and tapering off the medication.
Omada Health offers its own virtual care programs, so keep the source in mind when reading the results.
The Real Risks
The continuity-of-care concern centers on a few specific clinical scenarios:
Missing contraindications: If a telehealth provider reviews only the intake form and does not have your full medical records, they might miss something important, such as a personal or family history of medullary thyroid carcinoma or MEN 2 (listed contraindications on the Wegovy and Zepbound labels), or a history of pancreatitis (a label warning)[5][6].
Drug interactions: GLP-1 medications slow stomach emptying, which can affect how other oral medications are absorbed. The Zepbound label, for example, advises people using oral birth control to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase[6]. If different providers manage your medications, these interactions can go unnoticed without coordination.
Dose escalation decisions: GLP-1 medications are increased in steps. If you have side effects or your weight loss stalls, the decision to change the dose should be based on a complete clinical picture, not just a self-report.
Stopping the medication: At some point, you may want to reduce or stop the medication. Weight regain after stopping has been measured in trials: in the SURMOUNT-4 trial of FDA-approved tirzepatide, participants who switched to placebo after 36 weeks saw their weight rise by an average of 14.0% over the next 52 weeks, while those who continued lost an additional 5.5%[8]. Results vary. Trial results describe study participants and are not a prediction for any individual. Ask any provider how they handle tapering or stopping.
How Reputable Telehealth Programs Address These Gaps
Many GLP-1 telehealth programs describe safeguards like these. Ask which ones a program actually uses before you choose it:
- Detailed intake questionnaire: More than basic demographics. Health history, current medications, surgeries, allergies, and contraindication screening.
- Lab review before starting: Some programs require recent labs before a prescription decision. Labs can flag issues (such as kidney problems or blood sugar abnormalities) your prescriber should know about.
- Repeat labs at set intervals: Some programs ask for repeat labs during treatment to track kidney function, liver function, and metabolic markers. Ask whether labs are included in the price or billed separately.
- Messaging between visits: Some programs let you message the prescribing provider with questions or side effects. The provider can adjust dosing, address side effects, or set up a live visit if needed.
- Dose increases only after provider review: Ask whether a provider reviews how you are doing before each dose increase, or whether increases happen on a fixed schedule.
What Patients Should Do
If you choose telehealth for your GLP-1 prescription, here are specific steps to maintain good continuity of care:
Share your telehealth records with your PCP: Request a copy of your intake and lab results from the telehealth provider and send them to your PCP. This closes the information gap.
Bring your complete medication list to all appointments: Whether with your PCP or telehealth provider, make sure they have a current list of everything you are taking. Note the GLP-1 medication prominently.
Tell your providers before any surgery or procedure: GLP-1 medications slow digestion. The Wegovy and Zepbound labels warn that pulmonary aspiration has been reported in people taking GLP-1 medications who had general anesthesia or deep sedation, and tell patients to inform their providers before any planned surgery or procedure[5][6].
Use the provider messaging feature, if the program has one: If you have side effects or concerns between scheduled check-ins, contact your telehealth provider rather than waiting. Do not make dose changes on your own.
Keep up with any labs your provider orders: Labs are how a provider monitors kidney function, metabolic changes, or other issues. Skipping them creates the very continuity gap that PCPs worry about.
Can You Use Both?
Yes. These paths are not mutually exclusive. Some people use a telehealth program for their GLP-1 prescription while keeping their PCP for overall health care. The telehealth provider handles the GLP-1 prescription and any coaching the program includes. Your PCP handles everything else. Tell your PCP that you take a GLP-1 medication so they can factor it into any other medications or conditions they are managing.
The key is clear communication between your providers so everyone understands who is responsible for what.
What a Legitimate Telehealth Service Looks Like
If you choose the telehealth route, here is what to look for:
- A licensed provider who reviews each person’s intake individually (not automated approval) and is licensed in your state
- Clear requirements for labs before or during treatment, and who pays for them
- Clear, upfront disclosure of whether a medication is brand-name or compounded, and that compounded medications are not FDA-approved
- Written cancellation terms before you pay, including any minimum commitment
- A full cost breakdown: medication by dose, visits, labs, shipping, and any membership fee
- A clear plan for follow-up, side effect questions, and dose changes
- The name and license of the pharmacy that fills your prescription
Questions to Ask on Either Route
For your PCP or a specialist:
- Do you prescribe GLP-1 medications for weight management, and how often do you see patients on them?
- Does my plan cover them, and will your office submit the prior authorization if it is required?
- Which labs do you want before I start, and how often will we follow up?
- Who do I contact about side effects between visits?
For a telehealth program:
- Who would prescribe for me (physician, nurse practitioner, or physician assistant), and are they licensed in my state?
- Do you prescribe brand-name or compounded medication, and which pharmacy fills it?
- What is the total cost at each dose, including visits, labs, shipping, and membership fees? What are the cancellation terms?
- Do you work with insurance or help with prior authorization?
- How do follow-up, messaging, and dose increases work, and can you share my records with my PCP?
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] U.S. Census Bureau. Bunch LN, Ketema H. “Health Insurance Coverage in the United States: 2024.” Report P60-288. September 9, 2025. Accessed 2026-10-16. https://www.census.gov/library/publications/2025/demo/p60-288.html (Supports: 92.0 percent had health insurance for some or all of 2024.)
[2] 29 CFR 2560.503-1(f)(2) (claims procedure for employee benefit plans: urgent care and pre-service claim decision deadlines). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/29/2560.503-1
[3] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
[4] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. Accessed 2026-10-16. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Supports: tirzepatide shortage resolved 12/19/2024; semaglutide shortage resolved 2/21/2025; end dates of enforcement discretion periods.)
[5] Novo Nordisk. WEGOVY (semaglutide) prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[6] Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[7] Omada Health. “Doctors Report Concerns for Overprescribing and Continuity of Care for GLP-1s through Third-Parties.” Press release, February 13, 2025 (January 2025 survey of more than 2,000 U.S. primary care physicians). Accessed 2026-10-16. https://resourcecenter.omadahealth.com/for-employers/doctors-report-concerns-about-overprescribing-and-continuity-of-care-with-patient-access-to-glp-1-medications-through-third-party-telehealth
[8] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, does not bill insurance, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound, and they may differ in formulation, purity, and potency. Results vary. Trial results describe study participants and are not a prediction for any individual. Insurance and appeal information is general and does not represent your specific plan; confirm current details and deadlines with your plan. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.